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Aims: Evaluate the efficacy, safety, and tolerability of a novel pressure-attenuation balloon for the treatment of female
stress urinary incontinence (SUI) using a prospective, randomized, single-blind, multi-center design, evaluated at
3 months. Methods: Sixty-three females with SUI were randomized 2:1 to treatment with a balloon (N¼ 41) or sham
procedure (N¼ 22). The sham (control) entailed the same procedure without the deployment of a balloon. Endpoints were
evaluated at 3 months and included a composite endpoint that required both 10 point increase in the 22-item
Incontinence Quality of Life Survey (I-QOL) and50% decrease in provocative pad weight. Additional endpoints included
incontinence episode frequency, and PGII assessment. Results: In an ITT analysis, 63% of women in the treatment
group achieved the composite endpoint, compared to 31% in the Control Group (P¼0.0200). In a per protocol analysis,
81% of women in the treatment arm had a 50% decrease in pad weight test vs. 45% in the Control Group (P¼ 0.0143);
41.6% of the treatment patients were dry on pad weight test (1gram) vs. 0% in the Control Group (P<0.001), and 58% of
treated patients reported improvement on a PGII assessment versus 25% of women in the Control Group (P¼ 0.025).
Adverse events in the treatment group included dysuria (14.6%), gross hematuria (9.8%), and UTI (7.3%).
Conclusions: This minimally invasive treatment for female SUI with an intravesical pressure-attenuation balloon
was safe and effective. The concept of pressure attenuation as a therapy for SUI is valid and feasible for those patients that
can tolerate the balloon. Neurourol. Urodynam.
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INTRODUCTION
Stress urinary incontinence (SUI) typically results from
dysfunction of the urethral sphincter closure mechanism
and/or surrounding tissues, such that the urethra cannot resist
antegrade urine flow during periods of increased intra-
abdominal pressure.1 Current SUI treatments attempt to either
increase intrinsic urethral closure forces or increase urethral
support such that the urethra can better withstand transient
increases in intravesical pressure during stress maneuvers.2
This paper describes a novel technique for treating SUI that
focuses, instead, on directly reducing the transient spikes in
intravesical pressure that are common to all forms of SUI,
regardless of their etiology.
Because gas is highly compressible relative to most liquids, it
can act as a kind of hydraulic ‘‘shock-absorber.’’3 This concept is
fundamental to a wide range of air-filled pulsation dampeners
for minimizing hydraulic shock in industrial or civic plumbing
and fluid-handling systems. The capacity of a volume of gas to
absorb a pressure pulse in a closed hydraulic system is
proportional to the volume of gas, as expressed by Boyle’s
Gas Law.4 In industrial hydraulic systems, the compressible gas
is contained within some type of hydropneumatic attenuator.
In the system described in this paper, the gas is contained in an
intravesical balloon attenuator that is placed in the bladder to
directly attenuate the transient spikes in intravesical pressure
related to the increases in abdominal pressure. The fundamen-
tal mechanism of action for this intravesical application has
been described in previous published studies,5,6 including a
previous prospective, randomized, single-blind, multicenter
study on a different patient population.7
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This paper discusses the SOLECT trial, the second multicenter,
prospective, randomized, concurrently controlled and single
blinded study of an intravesical balloon to treat female patients
with predominate SUI (Vesair(TM), Solace Therapeutics, Fra-
mingham, MA). The goals of this study are to evaluate the
efficacy and safety of the balloon therapy against a control
sham procedure at three months. After the three-month data is
collected, the patients are unblinded and control patients are
offered to crossover and receive the balloon. Patients have the
option to continue with the balloon therapy and follow-up for
up to three years.
This article discusses the 3-month endpoint results compar-
ing treatment vs. control groups. Longer-term efficacy and
safety data for patients in the Treatment Group will be reported
when available.
PATIENTS AND METHODS
This study was conducted at seven sites in the European
Union under a clinical research protocol that was approved by
ethics committees for each site, and the devices are authorized
for sale in the European Union (CE Mark). Informed consent was
obtained from all subjects.
Prior to enrollment, all potential subjects were evaluated
using the following assessments: history and physical exami-
nation; laboratory urinalysis (including culture and sensitivity,
if urinalysis was positive); provocative pad weight test;
urodynamic evaluation, including VLPP; one seven-day voiding
diary; I-QOL; ICIQ-FLUTSsex; ICIQ-SF and cystoscopy.
The pad test was performed with controlled fill volumes and
activity levels. The patient voided normally and a weighed pad
was then placed. The patient then drank 500cc of fluid within
15 min. The bladder volume was monitored by bladder scan
until the measured volume was between 250 and 300 cc. The
patient underwent 30 min of walking and a specific series of
physical exercises while monitored by a blinded assessor. Upon
completion of the physical activity, the pad was immediately
removed and weighed. Patients are considered ‘‘dry’’ if their
post-test pad weight increase is 1g.
The study enrolled patients with SUI or MUI where stress
incontinence was the predominant component. Investigators
based this diagnosis by visually confirming stress incontinence
with physical maneuvers (stress test), urodynamics, and a
focused incontinence history/interview, all of which indicated
the predominance of a stress component. Additional inclusion
and exclusion criteria used during study recruitment are seen
in Table I. Randomization was sequential at each site using a
card-based randomization scheme. Patients were randomized
using a 2:1 randomization scheme in which one-third of
subjects (N¼ 22) were initially assigned to a Control Group
receiving a sham procedure, and two-thirds (N¼41) were
assigned to the Treatment Group (Fig. 1).
The study was powered to ensure adequate sample size for
testing the composite effectiveness endpoint. The PASS Power
Analysis and Sample Size software, 2011, by NCSS, was used for
computation of sample size requirements for the study
hypothesis. A level of 80% power was sought, using a two-
tailed test with alpha of 0.05. The estimate for proportion of
patients in the treatment group with this composite endpoint
is approximately 50%. The proportion of patients in the control
group for this trial (e.g., patients undergoing the sham
procedure) is estimated to be 12%. Using a two-sided Fisher’s
Exact test of the difference between two independent
proportions at the 0.05 level of significance and a 2:1
randomization ratio, a total of 56 patients are required to
detect an expected difference in proportion of patients with
this composite endpoint at 3 months of the magnitude
described above with 80% power. The sample size was
increased to 63 to offset loss to clinical follow-up.
Subjects in the treatment arm had the pressure attenuation
balloon inserted into the bladder on Day 0. For subjects in the
control arm, the identical procedure was used except a balloon
was not deployed from the balloon delivery system (subjects
were blinded as to whether they were in the treatment or
control arms; practitioners were necessarily unblinded). A
blinded assessor administered the endpoint instruments (pad
test and questionnaires) at the one-month and three-month
visits.
At one month, subjects in both arms completed the
following: 7-day voiding diary; I-QOL, PGII, ICIQ-SF and ICIQ-
FLUTSsex questionnaires. At three months, subjects in both
arms completed the following: provocative pad weight test; 7-
TABLE I. Inclusion and Exclusion Criteria
Inclusion Criteria: Females age 18 and older with SUI
Positive provocative pad weight test of 5 g
Experienced SUI for at least 12 months and failed prior noninvasive treatment
Willing to undergo cystoscopic and urodynamic procedures during the course of the study
Valsalva leak point pressure (VLPP) of 60 cm H20
Free of local genital skin infection, impassable urethral strictures, trauma or necrosis
Alert, oriented, mentally competent, and capable of determining their need to void by sensing and responding to an urge to void
A baselineI-QOL score of 80
Exclusion Criteria: Pregnant or planning pregnancy during study period
Urosepsis, Bladder infection, urethral inflammation, urethral
edema, urinary tract infection or asymptomatic bacteriuria within previous 3 months
Recurrent UTIs (2 or more in past 12 months)
Urinary incontinence due to intrinsic sphincter deficiency or of neurogenic etiology
Surgical procedure for incontinence in the past 6 months
History of artificial sphincter placement
Cystocele with bladder descent below mid-vagina during straining (PoP-Q grade 3)
Undergoing or anticipating a course of pelvic radiation therapy
Non-ambulatory or bedridden or physically unable to perform pad weight test
Presence of gross hematuria and/or blood clots in the urine
History of kidney stones
Detrusor overactivity or interstitial cystitis
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day voiding diary; I-QOL, PGII, ICIQ-SF and ICIQ-FLUTSsex
questionnaires. Endpoints were collected by a blinded assessor.
After all data was collected at the three month visit, all subjects
were unblinded as to their treatment group and patients in the
control group were offered to crossover and receive the balloon.
Prior to the 63 patient study reported herein, 17 patients were
enrolled at three centers. This enrollment was halted due to the
premature deflation of the balloon. Enrollment was reset and
the study was then started under the modified protocol and
device. All data and analysis herein includes only the 63
patients that were enrolled under the new protocol and device.
The composite endpoint of a 50% reduction in provocative
pad weight and a 10 point increase in I-QOL score was
evaluated at three months. Results were analyzed on both an
Intent-To-Treat (ITT) and Per Protocol (PP) basis with Student’s t
test used for comparison of means and Fisher’s Exact test for
comparison of proportions.
Adverse events were recorded at each follow-up visit
whenever reported by a patient or elicited by the site. ‘‘Urinary
Tract Infection’’ was defined as the presence of leukocytes
and/or bacteria in a urine specimen and/or urine cultures
demonstrating 100,000 or more colony forming units (CFU)
per ml of urine of a single bacterial species from a clean catch
mid-stream voided sample concurrent with dysuria, excessive
urinary frequency, excessive urge, purulent discharge from
the meatus, new onset of bladder symptoms, or gross
hematuria.
Procedure
Balloon placement. For patients in the Treatment Group, the
Guardian Urethral Sheath TM is placed through the urethra to
provide access to the bladder while protecting the urethra
(Fig. 2a). A scope is placed through the sheath to investigate the
bladder and then removed. The deflated balloon is pre-inserted
inside the tip of a 19 F delivery system. The delivery system is
inserted through the sheath and the deflated balloon is then
inflated with 0.5 cc of AirLocTM and 30 cc of air via two attached
syringes (Fig. 2b). AirLoc is a perfluorocarbon liquid used to
maintain inflation of the balloon. The inflated balloon is
released into the bladder and the insertion device is removed
from the sheath. Proper inflation of the balloon is verified
visually with a cystoscope through the sheath.
For patients in the Control Group, the Guardian Urethral
Sheath is placed through the urethra. A scope is placed through
the sheath to investigate the bladder and then removed. The
delivery system (without a deflated balloon at the distal tip) is
inserted through the sheath and the two syringes are deployed
to simulate balloon inflation. The release mechanism on the
delivery handle is deployed to simulate balloon release into the
bladder and the insertion device is removed from the sheath.
The lack of a balloon is then verified visually with a cystoscope
through the sheath.
Balloon removal. The balloon is removed when necessary under
direct visualization using a custom optical grasper through the
Fig. 1. CONSORT (CONsolidated Standards of Reporting Trials) Flow Diagram of SOLECT Study.
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sheath (Fig. 2c). The balloon is pierced to allow the air to escape,
then removed through the sheath. At the patient’s option, a
new balloon can be inserted through the sheath. At the end of
the procedure, the sheath is removed. All patients are
given prophylactic antibiotics prior to and after performing
cystoscopy, balloon insertion, sham balloon insertion or
removal.
RESULTS
Baseline characteristics between the treatment and control
groups were comparable for most parameters (Table II). The
composite endpoint was defined as the number of women in
either study arm who had both a 50% reduction in
provocative pad weight and a 10 point increase in their I-
QOL scores. Women in the treatment arm had significantly
improved symptoms when analyzed on both an ITT analysis
(63.4% in Treatment Group vs. 31.8% in Control Group;
P¼ 0.0200) (Fig. 3), and a per protocol analysis (67.7% in
treatment group vs. 31.6% in sham group; P¼0.0195).
Evaluable results for the composite endpoint were obtained
from 31 patients in the treatment arm and 19 patients in the
control arm (total¼ 50) (Fig. 1). Per the Statistical Analysis Plan
approved before the study began, the ITT analysis used
imputation for missing data.
Improvements were also observed in other endpoints,
analyzed on a Per Protocol basis (Table III). For example, a
statistically significant improvement in the percentage of
women with a greater than 50% reduction in their provocative
pad weight (80.7% of treated patients vs. 45% of the control
patients, P¼ 0.0143) was observed at three months. Further-
more, 41.9% of patients in the Treatment Group were ‘‘dry’’ on
their provocative pad weight test at three months compared to
0% of those who received the sham procedure (P¼ 0.0006). A
statistically significant improvement in symptoms was re-
ported on the patients PGII questionnaire, with 58.1% of
treatment patients reporting improvement versus 25% of the
control patients (P¼0.0249).
Eleven of 63 total enrolled subjects (17.4%) withdrew from
the study before the 3-month follow-up visit. Balloons were
removed from patients in the Treatment Group at the time of
withdrawal. The most significant reason for withdrawals was
related to issues of bladder irritation and tolerability of the
balloon and procedure. Six patients withdrew due to bladder
irritation, five of which exited before or during the 1-month
visit. Two patients exited due to dysuria, one of which occurred
5 days after balloon placement. One patient withdrew because
of concerns relating to UTI. One patient exited due to an
unsatisfactory therapeutic effect. In the control arm, one
patient exited due to a physical relocation to a foreign country.
Fig. 2. Solace procedure steps. A: Bladder access and fluid management A1: Insert tip of Guardian Urethral SheathTM into the urethra at the meatus. A2:
Advance Sheath into bladder, remove obturator, and fill bladder. A3: Insert scope through Sheath to visualize bladder. B: Balloon Delivery B1: Advance Solace
Balloon Delivery System (with deflated balloon at the tip) through Sheath and into bladder. B2: Inflate balloon with AirLocTM and air. B3: Squeeze trigger to
release balloon and remove Delivery System. Insert scope through Sheath to inspect balloon. C: Balloon Removal C1: Insert Solace Balloon Removal System
through Guardian Urethral Sheath and visualize balloon. C2: Squeeze removal handle to grasp and deflate balloon. C3: Pull Removal System and deflated
balloon through the Guardian Urethral Sheath. Insert scope through Sheath and visualize bladder.
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Careful evaluation was conducted on those pressure-
attenuation balloons that were removed during the 3-
month evaluation period to evaluate the balloons for
evidence of encrustation or sediment formation. Twelve
balloons were evaluated with a mean dwell time of 44.5
days (range from 5 days to 103 days) and were analyzed by
visual inspection. Some of the balloons changed color, and
some sediment was noticeable in the valve port of the
balloon, but no balloon had any measurable sediment
formation on the surface of the balloon. Chemical analysis
of a representative sample of the sediment indicated that it
was calcium oxalate. The twelve evaluated balloons includ-
ed one balloon removed from each of the 10 treatment
patients that withdrew, and one balloon removed from each
of two patients that had a balloon exchange at the
discretion of the investigator.
There was no observation of urinary retention or obstruction
and no patient complaints of incomplete emptying in either
study arm. No serious adverse events occurred during the 3-
month evaluation period. During the initial 3-month period,
device or procedure related adverse events were reported in 18
subjects in the Treatment Group (43.9%) compared with one
subject (4.6%) reporting a procedure-related adverse event in
the control group (Table IV). Three patients in the Treatment
Group had a UTI, all occurring within 22 days of balloon
placement. The UTI was resolved in one patient without
balloon removal. The other two patients had the balloon
removed by physician’s choice and the UTI resolved. One of
these patients exited the study, and the other had a new
balloon inserted after resolution of the infection. One patient
voided the fully inflated balloon at the end of micturition
shortly after balloon placement. A new balloon was replaced,
and the patient was instructed not to ‘‘bear down’’ to evacuate
all urine upon completion of voiding.
The presence of the balloon in the bladder did not result in
any clinical significant differences in the number of voids
per day. Patients in the Treatment Group had a mean voids/
day percent change of 6.0%, while the mean voids/day
percent change in the Control Group decreased 1.2%
(P¼0.3604).
TABLE II. Baseline Characteristics
Subject baseline characteristics Treatment N¼ 41 Control N¼ 22 P-value
Mean Age (years) 49.3 48.7 0.8638
Mean BMI 25.73 25.76 0.9761
Length of symptoms (Months) 90.9 78.5 0.5432
SUI Type 0.6104
Stress Only 95.0% 91.9%
Mixed 5.0% 9.1%
Cause of SUI 1.000
Hypermobility 88% 91%
ISD and Hypermobility, Predominant Hypermobility 12% 9%
Menopausal Status 0.0926
Pre-menopausal 46.3% 59.1%
Peri-menopausal 14.6% 27.3%
Post-menopausal 39.1% 13.6%
Number of Live Births (mean) 1.83 1.77 0.8170
Number of Vaginal Deliveries (mean) 1.80 1.77 0.8997
Other Symptoms Reported
Frequency 4.9% 9.1% 0.6063
Urge Incontinence 7.3% 0% 0.5457
Poor Stream 0% 4.6% 0.3492
Nocturia 7.3% 18.2% 0.2264
Urgency 9.8% 4.6% 0.6497
Straining 2.4% 0% 1.000
Hesitancy 7.3% 0% 0.5457
Mean Valsalva Leak Point Pressure 113.5 139.6 0.0235
Prior Treatments
Prior Pelvic Surgery (Any) 34.2% 22.7% 0.4011
Prior Hysterectomy 17.1% 4.5% 0.2425
Prior Failed Sling Procedure 9.8% 0% 0.2883
Prior Failed Bladder Training 43.9% 45.5% 1.000
Prior Failed Kegel Exercises 43.9% 50.0% 0.7917
Prior Failed Biofeedback 4.9% 13.6% 0.3327
Prior Failed Electrical Stimulation 7.3% 4.6% 1.000
Currently on Estrogen Replacement 0% 9.1% 0.1183
Current Tobacco User 17.1% 18.2% 1.000
Mean Packs/Day 1.0 1.0 1.000
Current Alcohol User 43.9% 54.6% 0.4418
Mean Drinks/Week 3.7 2.5 0.2131
Mean Baseline Measures
Pad Weight 27.2 24.9 0.7705
IQOL 51.8 51.1 0.8540
Leaks per day 3.1 2.4 0.2513
ICIQ FLUTSsex 3.8 3.4 0.5438
Voids/Day 7.3 6.7 0.2395
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DISCUSSION
Current SUI treatments focus on improving the urethral
closure forces such that the bladder outlet can better withstand
transient increases in intravesical pressure associated with
coughing, sneezing, exertion, or other actions that increase
intra-abdominal pressure. Despite a wide range of current
options, however, there remains a significant unmet clinical
need for non-surgical treatments that are effective across a
range of etiologies, and which are reversible, safe, relatively
inexpensive, and with low morbidity. The current study
suggests that this novel treatment focused on reducing rapid
changes in intravesical pressure may provide a clinically
valuable option that could be used alone or in combination
with existing therapies directed at urethral function.
The pressure attenuation balloon used in this study is
constructed of polyurethane, a material with a long history of
biocompatibility, including use in the urinary tract. A one-way
valve seals the balloon after being filled with 30 cc of air and
Airloc. AirLoc is a liquid perfluorocarbon used to maintain
inflation of the balloon. Liquid perfluorocarbons have been used
extensively in a number of FDA-approved medical devices
because they are inert, non-toxic, and safe.8 The balloon’s low
mass (0.2g) and inherent buoyancy causes it to float naturally
at the dome of the bladder, thus preventing occlusion of the
bladder outlet during voiding. By protocol and product labeling
TABLE III. Improvement at Endpoints
Follow-up measures (Change is from baseline)
One Month Three Month
Treatment Control P-value Treatment Control P-value
Provocative Pad Weight N¼ 31 N¼ 20
w/50% Reduction 80.7% 45.0% 0.0143
Dry (2 gm) 51.6% 15% 0.0164
Dry (1 gm) 41.9% 0% 0.0006
Mean Change (gm)   19.4   7.8 0.1830
Mean % Change   66.6% 15.9% 0.0072
I-QOL N¼ 38 N¼ 22 N¼ 31 N¼ 20
w/10 pt improvement 68.4% 59.1% 0.5766 74.2% 55.0% 0.2250
Mean Change 19.7 15.0 0.3873 22.7 13.3 0.1089
Mean % Change 53.3% 37.8% 0.3920 57.9% 35.5% 0.3223
Episode Frequency N¼ 32 N¼ 22 N¼ 31 N¼ 19
w/50% Reduction 59.4% 27.3% 0.0275 61.3% 31.6% 0.0792
Mean Change (leaks/day)   1.57   0.75 0.0816   1.28   0.44 0.2088
Mean % Change (leaks/day)   18.4%   9.4% 0.8117   41.7% 7.49% 0.0242
Dry (0 leaks/day) 12.5% 4.6% 0.6377 19.4% 0% 0.0707
Mean Change (Voids/day) 0.234   0.239 0.2228 0.373   0.113 0.3960
Mean % Change (Voids/day) 6.0%   1.8% 0.1862 5.7%   1.2% 0.3604
PGI-I N¼ 38 N¼ 22 N¼ 31 N¼ 20
Reporting Improvement 68.4% 36.4% 0.0294 58.1% 25.0% 0.0249
ICIQ-FLUTSsex N¼ 37 N¼ 21 N¼ 28 N¼ 19
Mean Change   0.97 2.86 0.0694   0.58   1.12 0.7360
Mean % Change   23.9% 8.8% 0.1297   38.1%   18.0% 0.3235
Fig. 3. Composite endpoint at 3 months (ITT analysis).
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(CE Mark), the balloon can be removed and replaced at any time
and has a recommended dwell time of up to 1 year. Longer
follow-up is required to determine the actual in-dwelling times
of balloons in this study.
Prior to the 63 patient study reported herein, 17 patients were
enrolled at three centers. This enrollment was halted due to the
premature deflation of the balloon. In five patients, the balloon
ruptured and deflated. In each case the balloon was voided by
the patient without incident. The balloon was strengthened
with an increase in wall thickness. Several protocol modifica-
tions were made to further exclude patients with predominate
urge symptoms, including the use of a completed 24 hr voiding
diary at patient evaluation and elimination of the hand
washing procedures during the provocative pad test. Enroll-
ment was reset and the study was then started under the
modified protocol and device. All data and analysis herein
includes only the 63 patients that were enrolled under the new
protocol and device.
The AE rates described herein are consistent with published
studies of bulking agents, with the added benefit of simple
removal of the implant at any time. The requirement of both
bacteria and symptoms in the definition of UTI was in the
protocol since the presence of a foreign body in the urinary tract
can result in symptoms such as pyuria and/or bacteriuria but
not necessarily infection. The adverse event rates, including
UTI, in this study were lower than those in a previous
randomized controlled trial of this technology reported by
Rovner et al in 2013.7 Device changes incorporated after the
previous study include the use of a seamless 30 cc balloon,
simplified delivery and removal instrumentation and proce-
dures, and the addition of a urethral sheath to minimize
urethral trauma and reduce the introduction of bacteria into
the bladder during balloon delivery and removal.
Limitations of the study include the unavoidable lack of
clinician blinding and a dropout rate in the treatment arm that
indicate that not all patients tolerate the balloon in their
bladder. All tolerability issues were resolved upon balloon
removal. Further study of those patients that didn’t tolerate the
balloon is underway to help further screen out patients that are
not good candidates for this therapy and to provide guidance
for future balloon modifications. The withdrawal rate should be
considered in the context that this approach is reversible, with a
very straightforward office procedure, at the patient’s option at
any time, and does not preclude any other subsequent therapy
options for the patient. The withdrawal rate herein is
consistent or better than other anti-incontinence products
such as pessaries9 and urethral plugs.10 The rigor of this trial,
requiring multiple visits and time consuming tests and
interventions, increased the patient burden beyond what
would be required in commercial use.
Statistical significance was achieved in the challenging
composite endpoint of this study, but the withdrawal rate
did have an impact on the statistical power of the study.
Imputation for missing data from withdrawn patients was
appropriate for the ITT analysis as withdrawals were primarily
due to lack of tolerability of the balloon, even though in many
cases the subjects reported an improvement in symptoms. It
would be misleading to negatively impact the assessment of
efficacy by imputing all withdraws as failures. Future studies
should include larger patient populations to minimize the
impact of early withdrawals.
A ‘‘perfect’’ therapy for SUI would be 100% effective, durable,
simple to implement, minimally invasive, completely revers-
ible, applicable for all types of SUI, relatively inexpensive, and
be associated with low morbidity and/or complications.11
Unfortunately, this ‘‘perfect’’ therapy does not exist. However,
the pressure attenuation system described herein moves us
closer to these ideals. For example, the inherent risks of surgery,
a permanent implant, and mesh are eliminated when
compared to mid-urethral slings.12 Given that the worldwide
number of patients with SUI is projected to grow to 167 million
by 2018,13 such a novel treatment option for SUI could have
wide applicability.
CONCLUSIONS
This randomized, controlled, sham trial compared efficacy
and safety outcomes for a novel intravesical pressure-attenua-
tion system designed to reduce or eliminate symptoms of SUI.
Results from the trial show statistically significant improve-
ments in clinically relevant objective and subjective measures
of SUI. The pressure attenuation system was safe and caused no
urinary retention during the 3-month follow-up period. This
therapy provides a useful alternative therapeutic option for
women with stress incontinence. Continued follow-up is
warranted to assess the long-term durability of this therapy.
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